Study wrapper · #161
Anterior Cutaneous Nerve Entrapment Syndrome From Glucagon-Like Peptide-1 Receptor Agonist Injection.
Editor's note
This is a single case report — the weakest design for causal inference, but valuable for pharmacovigilance. Clinicians describe a 44-year-old man who developed focal, nerve-type abdominal pain (anterior cutaneous nerve entrapment syndrome, ACNES) coinciding with starting tirzepatide injections; the pain improved after moving injections away from the abdomen and adding pain medication. The authors present it as the first documented ACNES case linked to a GLP-1-type injection. A case report cannot establish incidence, causation, or whether tirzepatide itself (versus the injection technique or site) is responsible — the temporal association and response to injection-site change are suggestive, not confirmatory. Its practical worth is a reminder to consider ACNES when focal abdominal pain appears with subcutaneous incretin therapy, and that relocating the injection site is a simple first step. Weigh it as a clinical signal and teaching case, not evidence of a common risk.
Plain-language abstract
This is a report of a single patient. A 44-year-old man developed sharp, focal abdominal pain of a nerve type — a condition called anterior cutaneous nerve entrapment syndrome (ACNES) — around the time he began injecting tirzepatide under the skin of his abdomen. Doctors diagnosed ACNES on examination, and his pain improved after he moved the injections away from the abdomen and started additional pain treatment. The authors say this appears to be the first reported case of ACNES linked to this type of injection. Because it describes just one person, the report cannot tell us how often this happens or prove the medication caused it; the injection site or technique may be involved. Its main lesson for clinicians is to keep ACNES in mind when someone has focal abdominal pain while using injectable GLP-1-type medications, and that simply changing where the injection is given may help.